129 related articles for article (PubMed ID: 20021268)
1. Evaluation of gonadotropin-releasing hormone agonist treatment for prevention of menstrual-related attacks in acute porphyria.
Innala E; Bäckström T; Bixo M; Andersson C
Acta Obstet Gynecol Scand; 2010; 89(1):95-100. PubMed ID: 20021268
[TBL] [Abstract][Full Text] [Related]
2. Effective treatment of severe menstrual migraine headaches with gonadotropin-releasing hormone agonist and "add-back" therapy.
Murray SC; Muse KN
Fertil Steril; 1997 Feb; 67(2):390-3. PubMed ID: 9022620
[TBL] [Abstract][Full Text] [Related]
3. Women with acute intermittent porphyria have a defect in 5α-steroid production during the menstrual cycle.
Innala E; Bäckström T; Poromaa IS; Andersson C; Bixo M
Acta Obstet Gynecol Scand; 2012 Dec; 91(12):1445-52. PubMed ID: 22924787
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder.
Segebladh B; Borgström A; Nyberg S; Bixo M; Sundström-Poromaa I
Am J Obstet Gynecol; 2009 Aug; 201(2):139.e1-8. PubMed ID: 19398092
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
Krause BT; Ohlinger R
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
[TBL] [Abstract][Full Text] [Related]
6. Immediate and delayed add-back hormonal replacement therapy during ultra long GnRH agonist treatment of chronic cyclical pelvic pain.
Al-Azemi M; Jones G; Sirkeci F; Walters S; Houdmont M; Ledger W
BJOG; 2009 Nov; 116(12):1646-56. PubMed ID: 19735378
[TBL] [Abstract][Full Text] [Related]
7. A gonadotropin releasing hormone analogue prevents cyclical attacks of porphyria.
Anderson KE; Spitz IM; Bardin CW; Kappas A
Arch Intern Med; 1990 Jul; 150(7):1469-74. PubMed ID: 2196028
[TBL] [Abstract][Full Text] [Related]
8. Add-back therapy in the treatment of endometriosis-associated pain.
Zupi E; Marconi D; Sbracia M; Zullo F; De Vivo B; Exacustos C; Sorrenti G
Fertil Steril; 2004 Nov; 82(5):1303-8. PubMed ID: 15533351
[TBL] [Abstract][Full Text] [Related]
9. Prolonged use of gonadotropin-releasing hormone agonist and tibolone as add-back therapy for the treatment of endometrial hyperplasia.
Agorastos T; Vaitsi V; Paschopoulos M; Vakiani A; Zournatzi-Koiou V; Saravelos H; Kostopoulou E; Constantinidis T; Dinas K; Vavilis D; Lolis D; Bontis J
Maturitas; 2004 Jun; 48(2):125-32. PubMed ID: 15172086
[TBL] [Abstract][Full Text] [Related]
10. Catamenial Acute Intermittent Porphyria Managed with GnRH Analogues and Estrogen and Progesterone Add-back Therapy.
Aggarwal A; Kulshreshtha B
J Pediatr Adolesc Gynecol; 2020 Aug; 33(4):432-434. PubMed ID: 32113877
[TBL] [Abstract][Full Text] [Related]
11. Cryopreserved-thawed embryo transfer in natural or down-regulated hormonally controlled cycles: a retrospective study.
Gelbaya TA; Nardo LG; Hunter HR; Fitzgerald CT; Horne G; Pease EE; Brison DR; Lieberman BA
Fertil Steril; 2006 Mar; 85(3):603-9. PubMed ID: 16500326
[TBL] [Abstract][Full Text] [Related]
12. Accelerated endometrial maturation in the luteal phase of cycles utilizing controlled ovarian hyperstimulation: impact of gonadotropin-releasing hormone agonists versus antagonists.
Saadat P; Boostanfar R; Slater CC; Tourgeman DE; Stanczyk FZ; Paulson RJ
Fertil Steril; 2004 Jul; 82(1):167-71. PubMed ID: 15237007
[TBL] [Abstract][Full Text] [Related]
13. Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis.
Regidor PA; Regidor M; Schmidt M; Ruwe B; Lübben G; Förtig P; Kienle E; Schindler AE
Gynecol Endocrinol; 2001 Jun; 15(3):202-9. PubMed ID: 11447732
[TBL] [Abstract][Full Text] [Related]
14. Early and late hormonal responses to the microdose gonadotropin-releasing hormone agonist in normal menstruating women.
Park WI; Kim SS; Chung HR; Shin SY; Lee JY
Fertil Steril; 2004 Apr; 81(4):1067-72. PubMed ID: 15066465
[TBL] [Abstract][Full Text] [Related]
15. Long-term effects of GnRH agonist, GnRH antagonist, and estrogen plus progesterone treatment on apoptosis related genes in rat ovary.
Saatli B; Kizildag S; Posaci C; Dogan E; Koyuncuoglu M; Ulukus EC; Atabey N
Fertil Steril; 2009 May; 91(5 Suppl):2006-11. PubMed ID: 18829022
[TBL] [Abstract][Full Text] [Related]
16. Gonadal protection by a gonadotropin-releasing hormone agonist depot in young women with Hodgkin's disease undergoing chemotherapy.
Franke HR; Smit WM; Vermes I
Gynecol Endocrinol; 2005 May; 20(5):274-8. PubMed ID: 16019373
[TBL] [Abstract][Full Text] [Related]
17. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
Elkind-Hirsch KE; Anania C; Malinak R
J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
[TBL] [Abstract][Full Text] [Related]
18. Dose effects of progesterone in add-back therapy during GnRHa treatment.
Cheung TH; Lo KW; Yim SF; Lam C; Lau E; Haines C
J Reprod Med; 2005 Jan; 50(1):35-40. PubMed ID: 15730171
[TBL] [Abstract][Full Text] [Related]
19. Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma.
Blumenfeld Z; Avivi I; Eckman A; Epelbaum R; Rowe JM; Dann EJ
Fertil Steril; 2008 Jan; 89(1):166-73. PubMed ID: 17601603
[TBL] [Abstract][Full Text] [Related]
20. Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women.
Sherman BM; Chapler FK; Crickard K; Wycoff D
J Clin Invest; 1979 Aug; 64(2):398-404. PubMed ID: 110834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
